Gene · 1902
Papers2,112
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,112
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The immunological landscape and silico analysis of key paraptosis regulator LPAR1 in gastric cancer patients. | Transl Oncol | 2024 | 39182362 | PubTator, text mining | PubMed |
| LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models. | Brain Behav Immun | 2024 | 39147172 | PubTator, text mining | PubMed |
| Impact of cellular ATP levels on cell viability in response to fluorouracil through lysophosphatidic acid (LPA) receptor-4 (LPA4) and LPA6 in colon cancer cells. | Adv Biol Regul | 2024 | 39024813 | PubTator, text mining | PubMed |
| Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis. | Eur Respir Rev | 2024 | 39009409 | PubTator, text mining | PubMed |
| Lysophosphatidic Acid (LPA) and Its Receptors in Mood Regulation: A Systematic Review of the Molecular Mechanisms and Therapeutic Potential. | Int J Mol Sci | 2024 | 39000547 | PubTator, text mining | PubMed |
| Hypoxia Promotes Invadosome Formation by Lung Fibroblasts. | Cells | 2024 | 38995003 | PubTator, text mining | PubMed |
| Roles of lysophosphatidic acid (LPA) receptor-mediated signaling in cancer cell biology. | J Bioenerg Biomembr | 2024 | 38886303 | PubTator, text mining | PubMed |
| Involvement of lysophosphatidic acid (LPA) receptor-mediated signaling in breast cancer cell functions by long-term tamoxifen treatment under hypoxic and estrogen-deprived conditions. | Pathol Res Pract | 2024 | 38875757 | PubTator, text mining | PubMed |
| Design and analysis of virtual impedance control scheme based on MESOGI for improving harmonic sharing of nonlinear loads. | Sci Rep | 2024 | 38858406 | PubTator, text mining | PubMed |
| Integrating transformers and many-objective optimization for drug design. | BMC Bioinformatics | 2024 | 38849719 | PubTator, text mining | PubMed |
| Lysophosphatidic acid promotes ESCC progression by increasing the level of CCL2 secreted by esophageal epithelial cells. | J Gene Med | 2024 | 38837511 | PubTator, text mining | PubMed |
| Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer. | Anticancer Drugs | 2024 | 38820067 | PubTator, text mining | PubMed |
| Differential transcriptional profiles of vagal sensory neurons in female and male mice. | Front Neurosci | 2024 | 38808032 | PubTator, text mining | PubMed |
| EnsemBic: An effective ensemble of biclustering to identify potential biomarkers of esophageal squamous cell carcinoma. | Comput Biol Chem | 2024 | 38759483 | PubTator, text mining | PubMed |
| Pharmacokinetics of Fipaxalparant, a Small-Molecule Selective Negative Allosteric Modulator of Lysophosphatidic Acid Receptor 1, and the Effect of Food in Healthy Volunteers. | Clin Pharmacol Drug Dev | 2024 | 38757472 | PubTator, text mining | PubMed |
| Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis. | Sci Rep | 2024 | 38719983 | PubTator, text mining | PubMed |
| Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer. | ChemMedChem | 2024 | 38648251 | PubTator, text mining | PubMed |
| Lysophosphatidic Acid Receptor 1 Plays a Pathogenic Role in Permanent Brain Ischemic Stroke by Modulating Neuroinflammatory Responses. | Biomol Ther (Seoul) | 2024 | 38627097 | PubTator, text mining | PubMed |
| Regulation of cellular responses to X-ray irradiation through the activation of lysophosphatidic acid (LPA) receptor-3 (LPA3) and LPA2 in osteosarcoma cells. | Pathol Res Pract | 2024 | 38615508 | PubTator, text mining | PubMed |
| Design, synthesis and evaluation of new thiazolidin-4-ones as LPA1 receptor antagonists for breast cancer therapy. | Future Med Chem | 2024 | 38578146 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1902/papers?page=6